Safety experts and former FDA inspector criticize the weakened bill
1 Sep 18 · 5d ago · 1 post · 1 source · development 1 of 2
Dr. Kevin Schulman and other experts argue the five-year delay undermines the bill's effectiveness, while Sens. Scott and Gillibrand defend the changes as necessary for FDA rulemaking and manufacturer compliance, though they call it a 'massive win for consumer safety and transparency.'
“Five years after it passes might as well be a lifetime.”
Dr. Kevin SchulmanSen. Rick Scott Bill sponsor
Sen. Kirsten Gillibrand Bill sponsorRetired Army Col. Vic Suarez Former medical supply-chain commanderDr. Kevin Schulman Stanford professor of medicine and health policyPeter Baker Former FDA inspector
The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump
Reported in the same hours no headline names this development itself — these 1 claim were published in its stretch
-
1 outlet “A Clear Watering Down”: Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate Vote
first by ProPublica, 5d ago
What people said 4 voices · best of 5 · verbatim
-
P
NEW: The Clear Labels Act was designed to help patients and doctors see exactly where a medication was made. But experts say the law’s most critical provisions have been cut: “It's just a clear watering down of the original bill.”
-
C
https://www. propublica.org/article/clear-l abels-act-drug-safety-senate-vote
-
The Clear Labels Act was designed to alert consumers to where their drugs are coming from. After two major changes to the bill, experts worry it won’t be as effective.
-
L
"You don't get to know if your meds are made in a contaminated factory because it might harm national security" is a new one. This is a great read (in a series of great reads from @propublica.org on this topic) from Naisha Roy.
All 2 developments of Senate strips drug transparency bill of key safety… →
MastodonNewswiresBlueskyHacker NewsReddit